Truist Financial
GMAB icon

Truist Financial’s Genmab GMAB Stock Holding History

Truist Financial’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.05M Sell
38,356
-3,701
-9% -$98.4K ﹤0.01% 1741
2026
Q1 		$1.13M Buy
42,057
+3,584
+9% +$107K ﹤0.01% 1630
2025
Q4 		$1.18M Buy
38,473
+11,756
+44% +$366K ﹤0.01% 1571
2025
Q3 		$819K Buy
26,717
+191
+0.7% +$4.65K ﹤0.01% 1775
2025
Q2 		$548K Sell
26,526
-2,463
-8% -$50.6K ﹤0.01% 1923
2025
Q1 		$568K Buy
28,989
+1,432
+5% +$30K ﹤0.01% 1797
2024
Q4 		$575K Sell
27,557
-17,619
-39% -$387K ﹤0.01% 1792
2024
Q3 		$1.1M Sell
45,176
-19,480
-30% -$521K ﹤0.01% 1481
2024
Q2 		$1.62M Buy
64,656
+2
+0% +$57 ﹤0.01% 1366
2024
Q1 		$1.93M Buy
64,654
+8,082
+14% +$237K ﹤0.01% 1291
2023
Q4 		$1.8M Sell
56,572
-5,805
-9% -$182K ﹤0.01% 1306
2023
Q3 		$2.2M Buy
62,377
+48,623
+354% +$1.85M ﹤0.01% 1187
2023
Q2 		$523K Sell
13,754
-61
-0.4% -$2.43K ﹤0.01% 1927
2023
Q1 		$522K Sell
13,815
-6,834
-33% -$263K ﹤0.01% 1954
2022
Q4 		$875K Buy
20,649
+71
+0.3% +$2.93K ﹤0.01% 1617
2022
Q3 		$662K Buy
20,578
+5,568
+37% +$196K ﹤0.01% 1675
2022
Q2 		$488K Sell
15,010
-1,408
-9% -$45.6K ﹤0.01% 1917
2022
Q1 		$594K Sell
16,418
-2,693
-14% -$92.4K ﹤0.01% 1905
2021
Q4 		$756K Sell
19,111
-2,003
-9% -$83.5K ﹤0.01% 1793
2021
Q3 		$923K Buy
21,114
+5,351
+34% +$240K ﹤0.01% 1659
2021
Q2 		$644K Sell
15,763
-2,294
-13% -$88.5K ﹤0.01% 1894
2021
Q1 		$593K Buy
18,057
+1,770
+11% +$66.6K ﹤0.01% 1878
2020
Q4 		$662K Buy
16,287
+425
+3% +$15.9K ﹤0.01% 1721
2020
Q3 		$580K Sell
15,862
-2,233
-12% -$80.7K ﹤0.01% 1646
2020
Q2 		$613K Buy
18,095
+4,687
+35% +$128K ﹤0.01% 1512
2020
Q1 		$284K Buy
13,408
+2,782
+26% +$62K ﹤0.01% 1891
2019
Q4 		$237K Buy
+10,626
New +$232K ﹤0.01% 2278

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Truist Financial's GMAB Position: Q2 2026 in Review

Truist Financial reduced its Genmab (GMAB) stake by 8.8% in Q2 2026, selling an estimated $98.4K and leaving 38,356 shares worth $1.05M. The position accounts for ﹤0.01% of the portfolio, ranked #1741.

Truist Financial first reported a position in GMAB in Q4 2019 and has held it in 27 quarters since. The position peaked at $2.2M in Q3 2023. 289 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Truist Financial held 38,356 shares of Genmab worth $1.05M as of Q2 2026.
  • Truist Financial sold 3,701 Genmab shares in Q2 2026, an estimated $98.4K.
  • Genmab made up ﹤0.01% of Truist Financial's portfolio in Q2 2026, its #1741 holding.
  • Truist Financial first reported a position in Genmab in Q4 2019 and has held it in 27 quarters since.
  • Truist Financial's Genmab position peaked at $2.2M in Q3 2023.
  • 289 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Truist Financial's 13F filing for Q2 2026, filed 28 Jul 2026.